Results 61 to 70 of about 133,754 (301)

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma

Frontiers in Oncology, 2020
Indoleamine 2,3-dioxygenase (IDO1) plays an important role in tumor immune evasion. In this study, we investigated the changes of tumor IDO1 expression and CD8+ tumor-infiltrating lymphocytes (TILs) status in tumor microenvironment (TME) after ...
Ruidi Jiao, Xiaoli Zheng, Yanan Sun, Zhuo Feng, Shuai Song, Hong Ge   +5 more
doaj   +1 more source

Intraoperative Collection of Ascitic Fluid With Intra‐ or Postoperative Reinfusion in Ovarian Cancer: Safety and Feasibility of a Roller Pumping Method

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell‐free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored.
Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami   +7 more
wiley   +1 more source

Deciphering the Dilemma: Choosing the Optimal Total Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Current Oncology
Rectal cancer management has evolved significantly, particularly with neoadjuvant treatment strategies. This narrative review examines the development and effectiveness of these therapies for locally advanced rectal cancer (LARC), highlighting the ...
Erik Manriquez, Sebastián Solé, Javiera Silva, Juan Pablo Hermosilla, Rubén Romero, Felipe Quezada-Diaz   +5 more
doaj   +1 more source

Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy

BMC Surgery, 2021
Objective To investigate the clinicopathological features and clinical efficacy among 101 cases of rectal gastrointestinal stromal tumors (GISTs) and to investigate the significance of imatinib mesylate (IM) neoadjuvant therapy.
Hongxin Yang, Chaoyong Shen, Xiaonan Yin, Zhaolun Cai, Qian Wang, Bo Zhang   +5 more
doaj   +1 more source

High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models. [PDF]

, 2016
Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse ...
Bouvet, Michael, Clary, Bryan M, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Murakami, Takashi, Suetsugu, Atsushi, Unno, Michiaki, Zhang, Yong, Zhao, Ming   +11 more
core   +3 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens. [PDF]

, 2020
BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy.
Cabral, Howard, Jones, Eric, Ko, Naomi, Leproux, Anais, Mehta, Rita S, O'Sullivan, Thomas, Pera, Vivian, Peterson, Hannah M, Roblyer, Darren, Tabassum, Syeda, Tank, Anup, Tromberg, Bruce J   +11 more
core  

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer [PDF]

, 2015
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common.
A Mackay, AK Dunbier, AK Dunbier, Alan Mackay, Alexey Larionov, Anita K Dunbier, Aradhana Rani, Ash Nerurkar, B Weigelt, BP Coe, C Curtis, C Kent, D Generali, DG Albertson, DS Tan, Elena López-Knowles, F Kreisel, Helen Anderson, HW Cheung, IE Smith, IE Smith, J Hicks, J Michael Dixon, Jorge S Reis-Filho, JS Foster, K Lundgren, L Osterberg, LA Martin, LA Martin, LA Martin, Lesley-Ann Martin, LG Leon, Lorna Renshaw, M Dowsett, M Mello-Grand, M Scaltriti, Mitch Dowsett, MJ Ellis, MT Weigel, N Turner, P Darbre, P Lal, Paul M Wilkerson, Peter Osin, PM Wilkerson, PM Wilkerson, PT Simpson, R Beroukhim, R Duprez, R Katz-Brull, R Natrajan, R Natrajan, R Natrajan, Ricardo Ribas, T Miyake, T Troiani, TK Lam, William R Miller, WR Miller, WR Miller, WR Miller, WR Miller, X Huo, Y Zhao, Z Ghazoui, Zara Ghazoui   +65 more
core   +3 more sources

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer [PDF]

JAMA Network Open, 2020
Standard therapy for locally advanced rectal cancer includes concurrent chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative strategy known as total neoadjuvant therapy (TNT) involves administration of CRT plus neoadjuvant chemotherapy before surgery with the goal of delivering uninterrupted systemic therapy to ...
Kasi, Anup, Abbasi, Saqib, Handa, Shivani, Al-Rajabi, Raed, Saeed, Anwaar, Baranda, Joaquina, Sun, Weijing   +6 more
openaire   +2 more sources